GSK un­veils long-term Shin­grix da­ta as shin­gles com­pe­ti­tion heats up

GSK’s mar­ket-lead­ing Shin­grix vac­cine proved ef­fec­tive against shin­gles more than 10 years post-ad­min­is­tra­tion, cre­at­ing a new hur­dle for a num­ber of po­ten­tial com­peti­tors.

Shin­grix was 82% ef­fec­tive against shin­gles af­ter 11 years, ac­cord­ing to an ex­ten­sion study in adults 50 years and old­er. In adults 70 years and old­er, Shin­grix main­tained a 73% ef­fi­ca­cy rate be­tween six and 11 years post-vac­ci­na­tion, GSK re­port­ed on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER